ADMP - Adamis Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.80
+0.15 (+4.11%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.65
Open3.75
Bid3.60 x 300
Ask3.80 x 900
Day's Range3.70 - 3.80
52 Week Range2.35 - 5.85
Volume192,671
Avg. Volume677,946
Market Cap126.882M
Beta0.64
PE Ratio (TTM)N/A
EPS (TTM)-0.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.75
Trade prices are not sourced from all markets
  • Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
    Zacks15 days ago

    Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs

    Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.

  • Adamis (ADMP) Surges Following Novartis Deal for Symjepi
    Zacks18 days ago

    Adamis (ADMP) Surges Following Novartis Deal for Symjepi

    Shares of Adamis (ADMP) skyrocket after the company signs a commercialization deal with Novartis for Symjepi.

  • ACCESSWIRE18 days ago

    Today's Research Reports on Stocks to Watch: Adamis Pharmaceuticals and MiMedx

    NEW YORK, NY / ACCESSWIRE / July 3, 2018 / Adamis Pharmaceuticals shares exploded on Monday after announcing that it has found a commercial partner for its allergic reaction treatment Symjepi. Shares of MiMedx Group fell hard after Wall Street learned the company's CEO and COO have both resigned amidst an ongoing investigation in the company's business practices. Adamis Pharmaceuticals Corporation shares closed up 50% on Monday with about 11.5 million shares traded.

  • MarketWatch18 days ago

    Adamis has a partner to market its EpiPen competitor after a year-long search

    Shares of biotech Adamis Pharmaceuticals Corp. soared more than 35% Monday, after the company said its search for a commercial partner for its competitor to Mylan N.V.’s EpiPen allergic reaction treatment is over. The Adamis (ADMP) product, called Symjepi, a syringe that’s filled with the allergic reaction treatment epinephrine, was approved by the U.S. Food and Drug Administration last July and patients have eagerly awaited its release.

  • The Wall Street Journal19 days ago

    [$$] Novartis Injects Itself Into Planned Rollout of EpiPen Competitor

    Swiss drug giant Novartis AG has bought the U.S. commercial rights to sell a potentially lower-cost alternative to Mylan NV’s EpiPen, the emergency treatment for allergic reactions that has been dogged by pricing and supply challenges. Novartis’s Sandoz generic-drug unit acquired the U.S. commercial rights for an emergency shot called Symjepi from Adamis Pharmaceuticals Corp., the companies said late Sunday.

  • Adamis Pharmaceuticals Rose Almost 35% Early on July 2
    Market Realist19 days ago

    Adamis Pharmaceuticals Rose Almost 35% Early on July 2

    On July 1, Adamis Pharmaceuticals (ADMP) announced an exclusive distribution and commercialization agreement for its Type I allergic reactions drug, Symjepi, with Novartis’ (NVS) subsidiary, Sandoz. Based on the agreement, Sandoz will hold commercial rights for the drug in the United States in exchange for upfront payment and performance-based payments. Adamis Pharmaceuticals retained the drug’s commercialization rights in markets outside the US.

  • TheStreet.com19 days ago

    Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor

    to make and distribute Adamis' product to treat allergic reactions. EpiPen product, to Novartis' Sandoz Inc. division, which will distribute and sell the 0.3 and 0.15 mg versions of Symjepi, according to a press release from Adamis. As part of the deal, Novartis will pay Adamis an upfront fee and potential future milestone payments, according to a press release.

  • Why Adamis (ADMP) Is Skyrocketing Today
    SmarterAnalyst19 days ago

    Why Adamis (ADMP) Is Skyrocketing Today

    Adamis Pharmaceuticals (NASDAQ:ADMP) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 45% upturn. The drug maker announced a strategic distribution and commercialization agreement with Sandoz, a subsidiary of industry juggernaut Novartis, for ADMP’s EpiPen alternative, Symjepi. Sandoz will have the first right of negotiation for Symjepi internationally and ADMP will continue to be able to develop additional offerings around its injection platform, Symject. The deal comes with an upfront payment and milestones (both not disclosed) to Adamis, as well as a 50/50 profit share (US).

  • GlobeNewswire20 days ago

    Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for Symjepi

    SAN DIEGO, July 01, 2018-- Adamis Pharmaceuticals Corporation announced today that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc., a division of the Novartis ...

  • ACCESSWIRE23 days ago

    Complimentary Technical Snapshots on Valeant Pharmaceuticals International and Three More Healthcare Stocks

    Stock Research Monitor: QTNT, ADMP, and PETS LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on VRX sign up now at www.wallstequities.com/registration . On Wednesday, June 27, ...

  • Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options

    Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock

    Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Associated Press2 months ago

    Adamis: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 23 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...

  • GlobeNewswire2 months ago

    Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update

    Adamis Pharmaceuticals Corporation (ADMP) today announced financial results and a business update for the first quarter ended March 31, 2018. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, said, “We have made a substantial amount of progress on several fronts since the beginning of the year.  The development of our product pipeline continues to move forward and we have several target milestones that we hope to reach later this year.  We believe the completion of these milestones will increase shareholder value. Symjepi ™ (epinephrine) Injection 0.15mg – The FDA determined that the company’s NDA for Symjepi ™ (epinephrine) Injection 0.15mg was sufficiently complete to permit a substantive review and indicated that no potential review issues were identified as of the date of the agency’s communication in February.  Approval is expected in the second half of this year.

  • Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
    Zacks3 months ago

    Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options

    Investors in Adamis Pharmaceuticals (ADMP) need to pay close attention to the stock based on moves in the options market lately.

  • High Growth Stocks To Invest In
    Simply Wall St.3 months ago

    High Growth Stocks To Invest In

    Robust, high-growth companies such as Adamis Pharmaceuticals are appealing to investors for many reasons. They bring about a strong upside to your portfolio, and less downside risk as opposed toRead More...

  • What Falling Estimates & Price Mean for Adamis Pharmaceuticals (ADMP)
    Zacks3 months ago

    What Falling Estimates & Price Mean for Adamis Pharmaceuticals (ADMP)

    Adamis Pharmaceuticals (ADMP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.